Clinical Research Directory

Inclusion Criteria: 1. Provision of informed consent prior to any study specific procedures; 2. Men and women 18 years and older; 3. Established indication for PCI according to the guidelines of ACC/AHA; 4. Native coronary lesion suitable for drug-eluting stent placement; 5. True bifurcation lesions (Medina 0,1,1/1,1,1), lesions length≤ 68 mm 6. Reference vessel diameter in side branch \> 2.5mm by visual estimation; 7. Complex bifurcation lesions based on the DEFINITION study. Exclusion Criteria: 1. Pregnancy and breast feeding mother; 2. Co-morbidity with an estimated life expectancy of \< 50 % at 12 months; 3. Scheduled surgery interrupting antiplatelet medications in the next 6 months; 4. Intolerable to DAPT; 5. Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk; 6. Unable to provide written informed consent, or fail to follow the protocol; 7. Previous enrolment in coronary intervention device investigation during the study period; 8. Lesion cannot be covered by 2 longest stents; 9. Restenotic bifurcation lesions； 10. Severe calcification requiring rotational atherectomy; 11. Acute myocardial infarction less than 24 hours; 12. Chronic total occlusion which is not recanalized; 13. Simple bifurcation lesions; 14. Renal failure requiring or during dialysis; 15. Hemoglobin \<9g/L 16. Uncontrolled hypertension (systolic blood pressure≥180 mmHg or diastolic blood pressure≥110 mmHg) 17. Severe heart failure (LVEF\<30%) 18. Combined pre- and post-capillary hypertension (mPAP≥25 mmHg, PCWP\>15 mmHg, and PVR\>3.0 WU) 19. Patients with hypertrophic obstructive cardiomyopathy.